Advicenne SA
3MM
Company Profile
Business description
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
Contact
2, rue Briconnet
NimesF-30 000
FRAT: +33 466055420
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
Fuel volatility can lead to short-term earnings swings but all players bear the cost almost equally.
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.10 | 29.10 | -0.32% |
| CAC 40 | 8,282.64 | 45.22 | -0.54% |
| DAX 40 | 24,063.60 | 19.38 | 0.08% |
| Dow JONES (US) | 48,535.99 | 317.74 | 0.66% |
| FTSE 100 | 10,620.68 | 11.62 | 0.11% |
| HKSE | 25,947.32 | 75.00 | 0.29% |
| NASDAQ | 23,639.08 | 455.35 | 1.96% |
| Nikkei 225 | 58,134.24 | 256.85 | 0.44% |
| NZX 50 Index | 13,076.58 | 59.32 | 0.46% |
| S&P 500 | 6,967.38 | 81.14 | 1.18% |
| S&P/ASX 200 | 8,978.70 | 32.70 | -0.36% |
| SSE Composite Index | 4,027.21 | 0.58 | 0.01% |